The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: evidences from a patient-derived primary culture case series in tridimensional and zebrafish models

Alessandro De Vita1, Federica Recine1,2, Giacomo Miserocchi1, Federica Pieri3, Chiara Spadazzi1, Claudia Cocchi1, Silvia Vanni1, Chiara Liverani1, Anna Farnedi3, Francesco Fabbri4, Valentina Fausti1, Roberto Casadei5, Francesca Brandolini5, Giorgio Ercolani5, Davide Cavaliere6, Alberto Bongiovanni1, Nada Riva1, Lorena Gurrieri1, Giandomenico Di Menna1, Sebastiano Calpona1, Silvia Angela Debonis1, Laura Mercatali1,† and Toni Ibrahim1,†

Abstract

Background: Soft tissue sarcomas (STS) are a rare group of solid neoplasm including among others liposarcoma, leiomyosarcoma (L-sarcoma) and undifferentiated pleomorphic sarcoma (UPS) entities. The current first-line treatment is represented by anthracycline based regimens, second-line may include trabectedin. Currently the activity of trabectedin and its mechanism of action is not completely elucidated.

Methods: Taking the advantages of our 3D patient-derived primary culture translational model we performed genomic-, chemobiogram, proteomic- and in vivo analysis in a UPS culture (S1). Furthermore pharmacological profiling of a UPS and L-sarcoma patient-derived case series and in silico analysis were carried out.

Results: Trabectedin exhibited an increased activity in 3D respect to 2D cultures suggesting an extracellular matrix (ECM) and timp1 involvement in its mechanism of action. Moreover 3D S1 xenotranspanted zebrafish model showed an increased sensitivity to trabectedin. Finally the results were further validated in a UPS and L-sarcoma case series.

Conclusions: Taken together these results confirmed the activity of trabectedin in these STS histotypes. Moreover the data underline the ECM involvement in the cytotoxic effect mediated by trabectedin and could open the door for researches aimed to focus on the patient setting that could benefit from this agent.

Keywords: Trabectedin, Extracellular matrix, Undifferentiated pleomorphic sarcoma and L-sarcoma, Patient-derived primary cultures, 3D scaffold, Chemotherapy
Background
The landscape of Soft Tissue Sarcoma (STS) consists in a variety of entities of mesenchymal origin with a 1% incidence among all adult cancers [1]. Till date, the World Health Organization (WHO) classification system identifies the existence of over 80 different histologic subtypes [2]. Among these, the most frequent STS in adults include: liposarcoma (LPS), leiomyosarcoma (LMS) and undifferentiated pleomorphic sarcoma (UPS) accounting 15%, 11% and 5%, respectively. Although they exhibit different biological and clinical heterogeneity, LPS and LMS are usually grouped under the name of L-sarcomas [3, 4].

Chemotherapy represents the standard clinical care in metastatic setting with very poor outcomes. Antineoplastic agents routinely administered as first-line chemotherapy include anthracyclines [5]. A variety of second-line options may be considered with no optimal standard sequential therapy established [3].

Trabectedin has been approved for the treatment of advanced STS patients following failure of first-line chemotherapy or as first-line treatment for patients unfit for anthracycline-based treatment [6].

This DNA-binding compound exhibits a pleiotropic antitumor activity and an indirect immunologic and antiangiogenetic effect involving the tumor microenvironment [7]. Although different translational and clinical studies focused on the role of trabectedin in STS patients were performed, its mechanism of action has not completely elucidated. In this regard, molecular evidences suggest that it acts via the binding of the DNA minor groove leading to the DNA double-helix distortion and breakage [8–10]. In addition to these cytotoxic effects, trabectedin has a role in modulating the tumor microenvironment and some evidences tend to identify this as the most important part of its therapeutic effect [11].

To explore the mechanisms behind antineoplastic effects of trabectedin in UPS and L-sarcomas we took the advantages of our 3D collagen-based scaffold culture system and zebrafish model combined with the use of patient-derived primary cultures. This prospective study aimed to shed the light on the activity of trabectedin in UPS and L-sarcoma patients, and potentially to better define optimal treatment strategies for STS patients in clinical setting.

Materials and methods

Case series
The study involved ten UPS and L-sarcomas patients surgically treated by experienced orthopedic and oncologic surgeons. The explanted tumor masses were analyzed by a sarcoma pathologist and processed within 3 h of surgical resection.

Ethical statement
The study protocol was approved by IRST-Area Vasta Romagna Ethics Committee (approval no. 4751, 31 July 2015). All the procedures were performed in accordance with GCP and Helsinki declaration. All the eligible participants gave written informed consent to take part in the study.

Next-generation sequencing
RNA isolation, purification and quality check was performed following the manufacturer’s instructions. NGS analysis was carried out as previously reported [12]. Further information are available in Appendix 2: Supplementary methods.

Collagen-based scaffold synthesis
The collagen scaffolds were synthesized as previously described [13–15]. Briefly, a 1 %-wt suspension of insoluble bovine type I collagen was prepared in 0.05 M of acetic acid solution. The material was cross-linked through a 1 wt% BDDGE solution. This suspension was mixed, frozen and then freeze-dried for 24 h. The obtained scaffolds were sterilized with ethanol 70% for 1 h and washed with PBS before using in cell culture.

Isolation of patient-derived UPS and L-sarcoma cells
Patient-derived primary cultures were established as previously described [16, 17]. The isolated primary cells were seeded in standard monolayer cultures at a density of 80.000 per cm$^2$ or in collagen-based scaffolds at a density of 500.000 cells/57 mm$^3$ and maintained in complete DMEM medium. Seeding on 3D collagen-based scaffolds was achieved as previously described [18, 19]. All the experiments were conducted using low-passage and proliferating primary cultures.

Gene expression profiling
mRNA isolation was obtained using TRIzol Reagent (Invitrogen) following the manufacturer’s instructions. iScript cDNA Synthesis Kit (BioRad) was used to reverse transcribe 500 ng of extracted RNA. Real-Time PCR was performed on the 7500 Real-Time PCR System using the TaqMan gene expression assay mix (Applied Biosystems). A total volume of 20 µL containing 2 µL of Taqman Universal PCR Master Mix (Applied Biosystems) and 2 µL of cDNA was used for the amplification. The amount of transcripts was normalized to the reference genes with the 2$\Delta\Delta$Ct method and expressed as n-fold mRNA levels relative to a calibrator (see complete list of genes in Supplementary Table S1). RNA extracted from the tumor tissue was used as calibrator.
Pharmacological and proteomic profiling
Primary tumor cells seeded both in standard plates and in 3D scaffolds were allowed to recover for 3 days and then were exposed to drugs. The regimens were selected according to peak plasma concentration of each drug from pharmacokinetic clinical data and they were: ifosfamide (IFO), epirubicin (EPI), combination of IFO + EPI, doxorubicin (DOXO), trabectedin (TRABE), eribulin (ERI), dacarbazine (DACA) and lenvatinib (LENV) (see complete list of chemotherapeutic in Supplementary Table S2). Cell viability percentage was assessed, as previously reported [20], through MTT reduction assay (Sigma Aldrich) after drug exposure for 72 h. Experiments were performed twice (see complete list of antibody in Supplementary Table S3).

Zebrafish xenograft
AB wild type zebrafish embryos (Appendix 2: Supplementary methods) obtained and stored according to Kimmel et al. [21] were dechorionated at 48 h post fertilization (hpf). Cells were labeled with a red fluorescent dye (CellTracker™ CM-DiI, Invitrogen) at the concentration of 2.5 × 10^5/µl. 300/500 cells were injected in the yolk sack of 48 hpf embryos. Grafted embryos with 2D or 3D cultured primary cells were divided in two groups that were treated with TRABE (PharmaMar) or no treated (20 zebrafish embryos per condition). Embryos were incubated at 32 °C for 72 h. Image of tumor area were performed using a fluorescence stereomicroscope (Nikon SMZ 25 equipped with NIS Elements software).

Statistical analysis
Two or three independent replicates were performed for each experiment. Data are presented as mean ± standard deviation or standard error, with n indicating the number of replicates. Differences between groups were assessed by a two-tailed Student's t-test and accepted as significant at \( p < 0.05 \).

Results
Patients
Clinical pathological characteristics of patients are reported in Table 1. Patient clinical history is available in Supplementary data information.

Establishment of a 3D patient-derived culture of high-grade UPS
The diagnosis of the surgically-resected tumor tissue (Fig. 1a and Supplementary Fig. S1) was high-grade polymorphic UPS. Molecular analysis of both MDM2 gene amplification and FUS-CHOP rearrangement were negative. NGS analysis of a STS fusions associated gene panel yielded no fusion call (Supplementary Fig. S2). Cytomorphologic features analysis of 2D and 3D primary cells confirmed the establishment of a patient-derived high grade UPS culture with a proportion of 20 and 45 % UPS cells respectively (Fig. 1b-c). In 2D the tissue-like organization was completely lost as in part the tumor cell morphology of the patient counterpart. In contrast the 3D model preserved a tissue-like organization with cell morphological features and distribution similar to that of tumor sample. Moreover a UPS and L-sarcoma primary culture case series was established for pharmacological profiling (Fig. 1e-f and Appendix 3: Supporting information).

Preservation of gene expression in 3D culture model
Markers involved in tumor aggressiveness were evaluated (Fig. 1d). Our model was able to preserve the expression of some markers belonging to several tumor-associated pathways respect to 2D culture. In particular \( tgf-b \) expression, was 33-fold lower than that of control in 2D while was 2.4 fold-higher increase in 3D. \( slug \) was 3.2-fold lower than that of control in 2D and 0.8-fold increase in 3D. \( snail \) was 5.4 fold-higher increase in 2D respect to that of the control and 0.5 in 3D compared to that of the control. Finally \( mmp9 \) was 25-fold lower than that of control in 2D and 0.1-fold lower in 3D.

Pharmacological profile of patient-derived high-grade UPS primary culture: 2D versus 3D
The role of chemotherapy in the UPS patient-derived S1 culture was investigated. S1 cultured in 2D and in 3D was exposed to IFO, EPI, to the combination of IFO and EPI and DOXO. Moreover, the efficacy of some second-line treatments as TRABE, ERI and DACA were evaluated. Finally, the activity of LENV, was assessed.

UPS cells cultured in 2D showed a survival of: 46 % with IFO, 14 % with anthracyclines-based regimens, 28 % with TRABE, 26 % with ERI, 30 % with DACA and 99 % with LENV (Fig. 2a-b). UPS cells cultured in 3D showed a survival of: 80 % with IFO, 27 % with anthracyclines-based regimens, 25 % with TRABE, 82 % with ERI, DACA did not affected the survival and 96 % with LENV (Fig. 2 a-b).

UPS cells cultured in 3D showed a survival of: 80 % with IFO, 27 % with anthracyclines-based regimens, 25 % with TRABE, 82 % with ERI, DACA did not affected the survival and 96 % with LENV (Fig. 2 a-b).

Significant differences between 2D and 3D treatments were detected for all the tested drugs excluding TRABE and LENV.

Next, the cell viability results were confirmed through a live-dead staining using flow cytometry analysis (Fig. 2c-d).

A higher sensitivity to treatments in 2D compared to 3D was observed in all treatment conditions while this was not evident with TRABE.
Table 1: Clinical pathologic characteristics of UPS and L-sarcoma patients enrolled in the study

| Patient | Sex | Age at surgery (years) | Site         | Size of major axis (cm) | Histological subtype | IHC analysis | Molecular cytogenetic analysis | Grade | Tumor        | Surgical margins | Radiotherapy post-surgery | Chemotherapy post-surgery | Follow up (months) |
|---------|-----|------------------------|--------------|-------------------------|----------------------|--------------|--------------------------------|-------|--------------|-------------------|--------------------------|--------------------------|---------------------|
| S1      | Female | 81 | lower arm | 13 | UPS | na | MDM2/CEP12 = 1 FUS (16p11)/10 % | G3 | Primary tumor | R1 | Yes | No | 26 |
| S2      | Female | 83 | gluteus | 2.5:1 | DDLPS | na | MDM2/CEP12 = 2 FUS (16p11)/10 % | G3 | Local recurrence | R1 | Yes | No | 46 |
| S3      | Female | 72 | lower arm | 15 | DDLPS | na | MDM2/CEP12 = 2 FUS (16p11)/10 % | G3 | Local recurrence | R0 | No | No | 14 |
| S4      | Female | 61 | thigh | 20 | ALT/WDLPS | na | MDM2/CEP12 = 2 FUS (16p11)/10 % | G3 | Primary tumor | R0 | No | No | 11 |
| S5      | Female | 77 | retroperitoneum | 10 | LMS | SMA + desmin + | MDM2/CEP12 = 2 FUS (16p11)/10 % | G2 | Primary tumor | R1 | No | No | 10 |
| S6      | Female | 71 | retroperitoneum | 10 | ALT/WDLPS | na | MDM2/CEP12 = 2 FUS (16p11)/10 % | G1 | Primary tumor | R1 | No | No | 12 |
| S7      | Male | 56 | trunk | 15 | ALT/WDLPS | na | MDM2/CEP12 = 2 FUS (16p11)/10 % | G1 | Primary tumor | R0 | No | No | 2 |
| S8      | Female | 78 | thigh | 6 | UPS | SMA + CD31 - CD34 - S100 - cytokeratins - desmin - CD117 - | MDM2/CEP12 = 1 FUS (16p11)/10 % | G3 | Primary tumor | R0 | Yes | No | 9 |
| S9      | Female | 57 | abdomen | 9 | DDLPS | na | MDM2/CEP12 = 2 FUS (16p11)/10 % | G3 | Primary tumor | R1 | No | No | 6 |
| S10     | Female | 64 | thigh | 7 | PLS | na | MDM2/CEP12 = 1 FUS (16p11)/10 % | G3 | Primary tumor | R1 | No | Yes | 4 |

IHC: immunohistochemical analysis, n/a: not applicable, SMA: smooth muscle actin, R0: microscopically margin-negative resection, R1: microscopically margin-positive resection
Chemotherapy induces apoptosis through the caspase-dependent apoptotic pathway in 3D high-grade UPS primary culture

To further determine how chemotherapy induces cytotoxic effect in S1, the expression levels of apoptotic- and anti-apoptotic-related proteins were assessed (Fig. 3). Casp-3 was upregulated in the negative control and in all treatment groups. In this regard no differences in the level expression between the control and treatment groups were observed in 2D (Fig. 3a-b), while in 3D the highest expression was observed in TRABE followed by the anthracycline-based regimens (Fig. 3c-d). The chemotherapy resistance related-gene MDM2 was upregulated in 2D in all treatment groups (Fig. 3a-b), while was downregulated with anthracyclines-based regimens, TRABE and LENVA and upregulated with IFO, ERI and DACA in 3D (Fig. 3c-d). Finally the MDM2 expression was also detected in the control in both 2D and 3D which is in line with patient diagnosis. The anti-apoptotic protein p21 was upregulated in the control and in all treatment groups in 2D and after IFO, ERI, DACA and LENVA treatments in 3D.

Metallopeptidase inhibitor timp1 seems associated to the activity of trabectedin in 3D

To better elucidate if the presence of the ECM components could affect the mechanism of action of the tested drugs, ECM-associated markers were evaluated in S1 cultured in 2D and 3D and compared to the expression of untreated cells. The expression of matrix modifying enzymes mmp2 and mmp9 and their inhibitor timp1 was analyzed (Fig. 4a-c).
Gene expression analysis of *mmp2* in 2D was significantly upregulated for all the tested drugs, meanwhile *mmp2* expression in 3D was significantly upregulated for IFO, EPI, DOXO, TRABE, ERI and DACA. A not significant upregulation was detected with IFO + EPI and LENVA.

Gene expression analysis of *mmp9* in 2D was: significantly upregulated for IFO, DACA and LENVA; not detected for anthracyclines based-therapy and TRABE, meanwhile *mmp9* expression in 3D was significantly upregulated for IFO; not detected for IFO + EPI and LENVA.

Gene expression analysis of *timp1* in 2D was: significantly upregulated for anthracyclines based-therapy, TRABE, ERI, meanwhile *timp1* in 3D was significantly upregulated for IFO, DOXO, TRABE, DACA and LENVA. A not significant upregulation was detected with EPI, IFO + EPI, ERI.

Since *timp1* is an inhibitor of *mmps* the *timp1/mmp2* and *timp1/mmp9* expression ratios in 2D and 3D were analyzed (Fig. 4d-e).

**Timp1/mmp2** relative expression ratio in 2D was: ≥ 1.0 for IFO, ERI, DACA, LENVA; < 1.0 for anthracyclines based-therapy, TRABE; meanwhile in 3D was ≥ 1.0 for anthracyclines based-therapy, TRABE; < 1.0 for IFO, ERI, DACA, LENVA.

**Timp1/mmp9** relative expression ratio in 2D was: ≥ 1.0 for ERI; < 1.0 for IFO, DACA, LENVA; undetermined for anthracyclines based-therapy and TRABE; meanwhile in 3D was ≥ 1.0 for EPI, TRABE, ERI; < 1.0 for IFO, DACA and LENVA; undetermined for IFO + EPI and DOXO.

**UPS primary cells cultured within collagen-based scaffold are more susceptible to trabectedin activity in zebrafish model**

In order to consolidate the data observed in vitro, S1 cultured in 2D and in 3D were xenotransplanted in zebrafish embryos (Supplementary Fig. S3). The engraftment was successfully achieved in both conditions. Tumor
growth imaged at 2 and 72 h post injection (hpi) showed equivalent fluorescence signals with both conditions at 2 hpi while at 72 hpi an increased signal of 3D condition was detected compared to 2D (Fig. 5a-b). Moreover in vivo cancer cells proliferation was significantly suppressed after 72h TRABE treatment in both 2D and 3D culture systems with the greater tumor growth inhibition rate in 3D (14% for 2D and 53% for 3D, Fig. 5c) compared to untreated group. Among all treated zebrafish embryos, the mortality was of 12.5 % and 4 embryos presented severe abnormalities (Supplementary Fig. S4) and were excluded from the study. No morphological abnormalities were detected in the untreated group.

The above observation prompted us to validate these data in a case series of STS patient-derived primary cultures.

**Trabectedin exhibited a higher activity in 3D and a comparable effect to anthracyclines in a UPS and L-sarcoma primary culture case series**

We investigated the activity of some first- and second-line treatments in UPS and L-sarcoma primary cultures. Established primary cultures (Fig. 1e-f and Appendix 3: Supporting information) were exposed to EPI, TRABE, ERI, DACA both in 2D and in 3D models (Fig. 6, Supplementary Fig. S5).

Among all patient the most active treatment were EPI and TRABE both in 2D and 3D (Fig. 6).

Significant increased activity in 3D with TRABE was observed for all patients excluding S2.

Significant increased activity in 3D with EPI was detected for S4-S6 and S8, and a decrease activity in S2, S3, S7, S9. No significant differences were detected in S10 patient.

No significant increased activity in 3D were observed with ERI and DACA.

**Discussion**

The aim of our study was to investigate the trabectedin activity in UPS and L-Sarcoma, thus we conceived a prospective study based on the use of patient-derived primary cultures combined with 3D culture system and zebrafish model. This study was carried out from June 2016 to February 2020 enrolling ten patients affected by UPS and L-sarcoma.
Our model exhibited, as previously shown [13, 22], a higher degree of morphological and genomics similarity to patient tumor compared to 2D system. Next, chemobiogram and FACS results (Fig. 2 a-d) revealed a significant increased S1 sensitivity for all tested drugs in 2D compared to 3D, confirmed also by Casp-3 upregulation in all treatment groups in 2D (Fig. 3a-b), no differences between 2D and 3D occurred with TRABE and LENVA (Fig. 2a-d). Thus we speculate that this evidence can be related to the mechanism of action exerted by these drugs. In particular, since TRABE and LENVA interfere respectively on tumor microenvironment modulation and in the vascular endothelial formation we can hypothesize their full spectrum of activity was underestimated in *in vitro* standard culture. The most active treatments were anthracyclines based-therapy and TRABE in 3D, confirmed also through Casp-3 proteomic analysis (Fig. 3c-d). These activity results observed between anthracyclines based-therapy and TRABE could provide support to the current use in clinical practice of TRABE as an up-front in elderly and frail people [3].

Furthermore, MDM2 downregulation mediated by LENVA in 3D could provide rationale for testing this drug in MDM2 amplified STS histotypes.

Based on the above results, we hypothesized that trabectedin might affect the S1 growth through a mechanism involving ECM-associated genes including *mmps* and their inhibitor *timp1* (Fig. 4a-c). The results showed a *timp1* upregulation in both 2D and 3D especially with anthracyclines-based regimens and TRABE (Fig. 4c). The above data are consistent with previous research [23] in which trabectedin seems to promote the increase of *timp1* expression which may affect the *mmps* activity contributing to the inhibition of cell invasiveness.

In this context, while *timp1* and *mmp2* were upregulated and *mmp9* was undetectable in 2D with TRABE, all of these genes were upregulated in 3D. This data suggested a possible saturation of *timp1* mediated-inhibition mechanism of *mmps* in 3D. This could serve as an explanation of the equivalent cytotoxic activity of TRABE detected between 2D and 3D (Figs. 3 and 4). This data was not observed with other tested drugs.

Moreover, while an increase in the *timp1/mmp2* ratio (Fig. 4d) between 2D and 3D does not improved the sensitivity to anthracyclines-based regimen this was observed in TRABE (Fig. 2a). In particular a lower sensitivity was expected in 3D, as observed for all the other tested drugs, while a similar trend was detected. The latter result could be related to the increased *timp1*/ *mmp2* ratio which could have affected the sensitivity to TRABE in 3D.
Furthermore, the higher \textit{timp1/mmp9} ratio observed in 3D in EPI (Fig. 4e) compared to TRABE was not related to an increased sensitivity of EPI in 3D (26\% for EPI and 25\% for TRABE). This result supports the above observation that \textit{timp1} could be involved with TRABE activity in 3D and not with other investigated drugs.

Indeed, the obtained results are corroborated by the missing correlation of \textit{timp1} activity with a higher sensitivity to chemotherapy in 3D with all the other tested drugs.

The \textit{in vitro} data were further validated in \textit{in vivo}. In particular, 3D S1 primary cells were more susceptible to TRABE also when injected into zebrafish embryos (Fig. 5c).

Previous results were validated in a UPS and L-sarcomas case series in which a significant increased activity in all 3D primary cultures was observed only with TRABE (Fig. 6). This evidence can be related to the unique trabectedin mechanism of action including a remodeling of ECM components and cells cytoskeleton. Moreover, as shown [22] our 3D model display an induction of biomarkers expression associated with STS pathogenesis (Fig. 1d) which could represent potential targets of TRABE. Furthermore, TRABE could affect the expression of ECM-related genes as collagen type 1 produced by tumor cells [24, 25] with suggestions that it may reduce the high turnover of the tumor stroma. Therefore results from a chondrosarcoma model showed that trabectedin prolonged exposure determine a decrease in mRNA expression of types I and IV collagen α1 chain which may be related to the drug resistance [8]. Finally, preclinical evidences suggested that trabectedin acts also via the inhibition of ECM degradation mediated by tumor cells causing the inhibition of cell invasiveness [23]. The above results provide support to our observations that the increased activity occurred in our study by trabectedin in 3D could be explainable by the presence of collagen type 1 compared to 2D culture.

S2 was the only primary culture among all that did not show the significant trend in favor of 3D observed with TRABE. This result is consistent with the clinical outcome observed in the patient, which showed a progression of disease during the first line with trabectedin therapy. One of the possible explanations could be related to the several local recurrences of DDLPS that could have promoted resistance of the patient to following treatments, compared to the other patients in which we tested the antitumor activity of TRABE in the primary tumor.

**Fig. 5** a Representative fluorescence microscopy images of zebrafish embryos xenotransplanted with S1 cultured in standard monolayer culture (2D) and within 3D collagen-based scaffold (3D). Images of embryos untreated at 2 and 72 h post injection and exposed to trabectedin at 72 h post injection, scale bar 1000 μm. b Mean fluorescence signal of 2D and 3D xenotransplanted embryos, arbitrary units. c Tumor growth inhibition rate between 2D and 3D groups.
A similar trend was observed with EPI in only a half of analyzed cultures, showing considerable variations in the sensitivity of the three main subtypes of LPS, LMS and UPS to anthracyclines. This evidence could suggest a possible predominant cytotoxic effect mediated by EPI rather than an involvement of ECM.

Moreover the results of another DNA-binding drug as EPI suggest that the activity of TRABE in 3D is not related to the ability of our 3D model in selecting an increased tumor cell population but to the ECM involvement in the mechanism of action of this drug. Furthermore, in silico analysis (Appendix 3: Supporting information) showed the upregulation of the ECM component col1a1 in various tumors (Supplementary Fig. S6). Noteworthy, the highest expression was observed in STS followed by breast invasive carcinoma. Trabectedin has been approved for the treatment of advanced STS patients and its activity has been also showed in breast invasive carcinoma [26]. Taken together these results are supporting the ECM involvement in the activity of trabectedin. Moreover timp1 exhibited a positive prognostic role in STS disease free survival and mmp2 was upregulated in various tumors with the highest expression in STS (Supplementary Fig. S7) supporting their role in STS disease.

**Conclusions**

In conclusion the results of this study are suggestive of the great contribution mediated by culturing models and primary cultures [27] in treatment response. On the
other side our study presented several limitations. The small number of patients involved and the heterogeneity in primary cultures tumor cells may be correlated to a variability of the results. Moreover preclinical model fails to completely reproduce the spectrum of all tumor features. Another criticism is represented by the use of ifosfamide instead of its active metabolite. Our tentative to limit this bias lies on the coupling of different approaches including in vitro 3D system, the use of primary cultures, and an in vivo model.

Overall, our results are consistent with the clinical evidence that trabectedin is effective in L-sarcomas [28, 29], however some retrospective and randomized trials suggested an antitumor activity of trabectedin in non-L-sarcomas including UPS [30, 31]. In this regard, the clinical relevance of our study is represented by the potential use of trabectedin also for the STS characterized by an aggressive behavior, as UPS.

To the best of our knowledge this is the first translational work on a UPS and L-sarcoma 3D patient-derived primary cultures case series in which the role of chemotherapy and especially trabectedin was investigated. Moreover, this is the first research in which the activity of trabectedin has been analyzed in vivo through the use of UPS primary culture in zebrafish model.

Ongoing clinical trials are focusing on the activity of trabectedin in mono-regimen or in combination with novel drugs for STS treatment (NCT03985722, NCT02398058).

The results of this study shed the light on the potential role of ECM in the mechanism of action of trabectedin in some of most frequent STS histotypes in adults. The work underlines the involvement of this tumor microenvironment component in predicting response to trabectedin and provide the rationale for better stratifying patients which would be candidate for this drug. Further researches are needed to confirm these evidences.

Abbreviations
ALT/WDLPS: Atypical lipomatous tumor or well-differentiated; BDDGE: 1,4-butanediol diglycidyl ether; casp-3: Cysteine-aspartic acid protease; col1a1: Collagen type I alpha 1 chain; CT: Computed tomography; DACA: Dacarbazine; DDLPS: Dedifferentiated liposarcoma; DMEM: Dulbecco’s modified Eagle’s medium; ECM: Extracellular matrix; EPI: Eribulinic; ER: Eribulin; FISH: Fluorescence in situ hybridization; GEPIA 2: Gene expression profiling integrative analysis 2; H&E: Hematoxylin and eosin; Hpi: Hours post injection; IFO: Ifosfamide; IFO+EPI: Ifosfamide+epirubicin; LENVA: Lenvatinib; LMS: Leiomyosarcoma; UPS: Liposarcoma; MDM2: Mouse double minute 2 homolog; MLPS: Myxoid liposarcoma; mmp2: Matrix metalloproteinase 2; mmp9: Matrix metalloproteinase 9; MR: Magnetic resonance imaging; p21: Cyclin-dependent kinase inhibitor 1; PET: Positron emission tomography; PLS: Pleomorphic sarcoma; pSMA: Smooth muscle actin; snail: Zinc finger protein SNAI1; STS: Soft tissue sarcoma; SUV: Standard uptake value; TAM: Tumor-associated macrophages; tsga: The Cancer Genome Atlas; tgf-b: Transforming growth factor-beta; TIMEr: Tumor IMmune Estimation Resource; timp1: TIMP metalloproteinase inhibitor 1; tpm: Transcripts per million; TRABE: Trabectedin; UPS: Undifferentiated pleomorphic sarcoma; WHO: World Health Organization

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13046-021-01963-1.

Acknowledgements
The authors thank EISAI for kindly providing lenvatinib, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) “Dino Amadori” Oncology Pharmacy unit for kindly providing the tested drugs, the IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) “Dino Amadori” Advanced and Predictive Molecular Diagnostic unit for kindly providing support for next-generation sequencing analysis and Gráinne Tierney for editorial assistance.

Authors’ contributions
A.D.V., L.M. and T.I. conceived the idea for the study. A.D.V., G.M., F.P., C.S., C.C., S.V., C.L., A.F. and F.F. performed the experiments; R.C., F.B., G.E. and D.C. performed the surgery and provided the surgical specimens. A.D.V., F.R., F.P., V.F., A.B., N.R., L.G., G.D.M., S.C., S.A.D., L.M. and T.I. were responsible for data interpretation. A.D.V. drafted the paper. All authors read and approved the final version of the manuscript for submission.

Funding
The present study was supported by the Italian Ministry of Health and Alleanza Contro il Cancro (ACC) sarcoma working group.

Availability of data and materials
The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The study protocol was approved by IRST-Area Vasta Romagna Ethics Committee (approval no. 4751, 31 July 2015). All the procedures were performed in accordance with GCP and Helsinki declaration. All the eligible participants gave written informed consent to take part in the study.

Consent for publication
No identifiable images were included in the manuscript.

Competing interests
The authors declare that there are no competing interests.

Author details
1Osteoncology and Rare Tumors Center, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) “Dino Amadori”, Meldola, Italy. 2Medical Oncology Unit, San Camillo de Lellis Hospital, Biet, Italy. 3Pathology Unit, Morgagni-Pierantoni Hospital, Forlì, Italy. 4Biosciences Laboratory, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) “Dino Amadori”, Meldola, Italy. 5Orthopedic Unit, Morgagni-Pierantoni Hospital, Forlì, Italy. 6Department of Medical and Surgical Sciences - DIMEC, University of Bologna, Bologna, Italy.

Received: 27 November 2020 Accepted: 26 April 2021
Published online: 11 May 2021

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics. 2019. CA Cancer J Clin. 69; 7–34 (2019). https://doi.org/10.3322/caac.21565.
2. Fletcher CD. The evolving classification of soft tissue tumors – an update based on the new 2013 WHO classification. Histopathology, 2014;64:2–11. https://doi.org/10.1111/his.12267.
3. Casali PG, Abe cassis N, Bauer S, Bauer S, Biagini R, Bielack S, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN clinical practice guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 2018;29(1):51-67. https://doi.org/10.1093/annonc/mdy096.
4. Ducimetière F, Lurkin A, Racine F, Mercatali L, Miserocchi G, Liverani C, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One. 2011;6:e20294. https://doi.org/10.1371/journal.pone.0020294.
5. Juddon I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15:415–23. https://doi.org/10.1016/S1470-2045(14)70063-4.
6. Carter NJ, Keam SJ. Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer. Drugs. 2010;70:355–76. https://doi.org/10.2165/1120860-0000000000-00000.
7. Zewail-Foote M, Hurley LH. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem. 1999;42:1493–7. https://doi.org/10.1021/jm990241l.
11. Miserocchi G, Mercatali L, Liverani C, De Vita A, Spadazzi C, Pieri F, et al. Management and potentialities of primary cancer cultures in preclinical and translational studies. J Transl Med. 2017;15:2229. https://doi.org/10.1186/s12967-017-1238-z.
12. Demeti GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016;34:786–93. https://doi.org/10.1200/JCO.2015.62.4734.
13. Demeti GD, Chavla SP, von Mehren M, Ritch P, Baker HL, Blay JY, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27:4188–96. https://doi.org/10.1200/JCO.2008.21.0088.
14. De Sanctis R, Menni A, Marchetti S, Musi C, Balzarini L, Lutman FR, et al. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma. Drug Des Devel Ther. 2015;9:5785–91. https://doi.org/10.2147/DDDT.S92395.
15. Holcik M, Grabelius F, Podleska L, Ahrens M, Schwinderhammer B, Taeger G, et al. Trabectedin in metastatic soft tissue sarcomas: role of pretreatment and age. Int J Oncol. 2013;43:23–43. https://doi.org/10.3892/ijo.2013.1928.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.